Your browser doesn't support javascript.
loading
Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.
Yamayoshi, Seiya; Nagai, Etsuko; Mitamura, Keiko; Hagihara, Masao; Kobayashi, Ryo; Takahashi, Satoshi; Shibata, Akimichi; Uwamino, Yoshifumi; Hasegawa, Naoki; Iqbal, Asef; Kamimaki, Isamu; Iwatsuki-Horimoto, Kiyoko; Nagamura-Inoue, Tokiko; Kawaoka, Yoshihiro.
Afiliação
  • Yamayoshi S; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Nagai E; International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Mitamura K; Research Center for Global Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Hagihara M; Department of Laboratory Medicine, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Kobayashi R; Division of Infection Control, Eiju General Hospital, Tokyo, Japan.
  • Takahashi S; Department of Hematology, Eiju General Hospital, Tokyo, Japan.
  • Shibata A; Division of Laboratory Medicine, Sapporo Medical University Hospital, Sapporo, Japan.
  • Uwamino Y; Department of Infection Control and Laboratory Medicine, Sapporo Medical University, Sapporo, Japan.
  • Hasegawa N; Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, Tochigi, Japan.
  • Iqbal A; Department of Pediatrics, School of Medicine, Keio University, Tokyo, Japan.
  • Kamimaki I; Department of Laboratory Medicine, School of Medicine, Keio University, Tokyo, Japan.
  • Iwatsuki-Horimoto K; Department of Infectious Diseases, School of Medicine, Keio University, Tokyo, Japan.
  • Nagamura-Inoue T; Department of Pediatrics, NHO Saitama Hospital, Saitama, Japan.
  • Kawaoka Y; Department of Pediatrics, NHO Saitama Hospital, Saitama, Japan.
Epidemiol Infect ; 152: e24, 2024 Jan 23.
Article em En | MEDLINE | ID: mdl-38258464
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 in China and rapidly spread worldwide, leading to a pandemic. The threat of SARS-CoV-2 is subsiding as most people have acquired sufficient antibodies through vaccination and/or infection to prevent severe COVID-19. After the emergence of the omicron variants, the seroprevalence of antibodies against the N protein elicited by SARS-CoV-2 infection ranged from 44.4% to 80.2% in countries other than Japan. Here, we assessed the seroprevalence in Japan before and after the appearance of omicron variants. Serosurveillance of antibodies against N was conducted between December 2021 and March 2023 in Japan. In total, 7604 and 3354 residual serum or plasma samples were collected in the Tokyo metropolitan area and Sapporo, respectively. We found that the seroprevalence in representative regions of Japan increased approximately 3% to 23% after the emergence of the omicron variants. We also found higher seroprevalence among the young compared with the elderly. Our findings indicate that unlike other countries, most of the Japanese population has not been infected, raising the possibility of future SARS-CoV-2 epidemics in Japan.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Aged / Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Aged / Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article